Compare · BDX vs WOK
BDX vs WOK
Side-by-side comparison of Becton Dickinson and Company (BDX) and WORK Medical Technology Group LTD (WOK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and WOK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $52.78B, about 8816.0x WOK ($6.0M).
- BDX has hit the wire 9 times in the past 4 weeks while WOK has been quiet.
- BDX has more recent analyst coverage (25 ratings vs 0 for WOK).
- Company
- Becton Dickinson and Company
- WORK Medical Technology Group LTD
- Price
- -
- -
- Market cap
- $52.78B
- $6.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 9
- 0
- Recent ratings
- 25
- 0
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Latest BDX
- BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026
- BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide
- BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
- BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan
- BD Appoints Ferass Abuzaina as Worldwide President of Surgery
- BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare Resilience
- EVP, Chief Revenue Officer Feld Michael sold $13,961 worth of shares (76 units at $183.70) as part of a pre-agreed trading plan, decreasing direct ownership by 0.39% to 19,644 units (SEC Form 4)
- BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
- Arthur Hu to Join BD as Chief Information and Digital Officer
- BD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at Fairview
Latest WOK
- SEC Form 6-K filed by WORK Medical Technology Group LTD
- SEC Form 6-K filed by WORK Medical Technology Group LTD
- Large owner Hrt Financial Lp bought $40,501 worth of shares (880,456 units at $0.05) and sold $528,894 worth of shares (136,665 units at $3.87), decreasing direct ownership by 68% to 123,944 units (SEC Form 4)
- Large owner Hrt Financial Lp bought $25,548 worth of shares (268,927 units at $0.10) and sold $168,465 worth of shares (2,904,567 units at $0.06), decreasing direct ownership by 87% to 391,456 units (SEC Form 4)
- Large owner Hrt Financial Lp bought $3,849 worth of shares (48,108 units at $0.08), increasing direct ownership by 2% to 3,027,096 units (SEC Form 4)
- WORK Medical Announces 1-for-100 Reverse Stock Split Effective June 18, 2026
- Large owner Hrt Financial Lp bought $363,500 worth of shares (3,794,711 units at $0.10) (SEC Form 4)
- New insider Hrt Financial Lp claimed ownership of 949,661 shares (SEC Form 3)
- Large owner Hrt Financial Lp sold $363,617 worth of shares (3,463,022 units at $0.10), closing all direct ownership in the company (SEC Form 4)
- Large owner Hrt Financial Lp bought $239,679 worth of shares (2,261,118 units at $0.11), increasing direct ownership by 586% to 2,647,299 units (SEC Form 4)